MX2021007551A - Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas. - Google Patents

Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas.

Info

Publication number
MX2021007551A
MX2021007551A MX2021007551A MX2021007551A MX2021007551A MX 2021007551 A MX2021007551 A MX 2021007551A MX 2021007551 A MX2021007551 A MX 2021007551A MX 2021007551 A MX2021007551 A MX 2021007551A MX 2021007551 A MX2021007551 A MX 2021007551A
Authority
MX
Mexico
Prior art keywords
treatment
neurodegenerative diseases
bile acids
fluorinated
fluorinated bile
Prior art date
Application number
MX2021007551A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Charles Weymouth-Wilson
Bruno Jan Pol Linclau
Gemma Packer
Joseph WATTS
Heather Mortiboys
Oliver Bandmann
Christopher Hastings
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2021007551A publication Critical patent/MX2021007551A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021007551A 2018-12-20 2019-12-20 Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas. MX2021007551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820887.6A GB201820887D0 (en) 2018-12-20 2018-12-20 Compounds
PCT/GB2019/053665 WO2020128514A1 (en) 2018-12-20 2019-12-20 2-fluorinated bile acids for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
MX2021007551A true MX2021007551A (es) 2021-10-13

Family

ID=65364420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007551A MX2021007551A (es) 2018-12-20 2019-12-20 Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas.

Country Status (15)

Country Link
US (1) US20220073557A1 (cg-RX-API-DMAC7.html)
EP (1) EP3898645B1 (cg-RX-API-DMAC7.html)
JP (1) JP7503063B2 (cg-RX-API-DMAC7.html)
KR (1) KR102856276B1 (cg-RX-API-DMAC7.html)
CN (1) CN113330020B (cg-RX-API-DMAC7.html)
AU (1) AU2019411556B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123333A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191521A1 (cg-RX-API-DMAC7.html)
ES (1) ES3036094T3 (cg-RX-API-DMAC7.html)
GB (1) GB201820887D0 (cg-RX-API-DMAC7.html)
IL (1) IL284093B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007551A (cg-RX-API-DMAC7.html)
SG (1) SG11202105465WA (cg-RX-API-DMAC7.html)
WO (1) WO2020128514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4486318A4 (en) * 2022-03-02 2026-02-25 Boyce Thompson Institute For Plant Res Inc Cysteamides, related therapeutic compositions and associated processes
GB202208151D0 (en) 2022-06-01 2022-07-13 Nzp Uk Ltd Compounds
GB202314563D0 (en) 2023-09-22 2023-11-08 Nzp Uk Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
FR2934596B1 (fr) * 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
ITMI20121344A1 (it) * 2012-07-31 2014-02-01 Erregierre Spa Processo di preparazione di acido ursodesossicolico ad elevata purezza
WO2014036379A2 (en) * 2012-08-31 2014-03-06 Metselex Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases
CN103333216A (zh) * 2013-06-04 2013-10-02 苏州大学 5α-6-酮-胆甾烷类似物及其应用
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
CN107531741A (zh) * 2015-03-10 2018-01-02 美莱斯股份有限公司 氟化和烷基化胆酸
GB201812382D0 (en) * 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Also Published As

Publication number Publication date
WO2020128514A1 (en) 2020-06-25
EP3898645C0 (en) 2025-06-25
CA3123333A1 (en) 2020-06-25
JP7503063B2 (ja) 2024-06-19
ES3036094T3 (en) 2025-09-12
GB201820887D0 (en) 2019-02-06
CN113330020A (zh) 2021-08-31
EP3898645A1 (en) 2021-10-27
AU2019411556A1 (en) 2021-06-10
IL284093B2 (en) 2025-07-01
IL284093B1 (en) 2025-03-01
JP2022514401A (ja) 2022-02-10
BR112021011189A2 (pt) 2021-08-31
KR102856276B1 (ko) 2025-09-05
AU2019411556B2 (en) 2025-04-03
EA202191521A1 (ru) 2021-09-10
US20220073557A1 (en) 2022-03-10
CN113330020B (zh) 2024-04-05
IL284093A (en) 2021-08-31
EP3898645B1 (en) 2025-06-25
KR20210125982A (ko) 2021-10-19
SG11202105465WA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
MX2020000261A (es) Nuevos compuestos.
ECSP066879A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CO2019007835A2 (es) Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
BR112013001015A2 (pt) método por tratar doenças oftálmicas que usam compostos de inibidor de cinase em formas de prodrug
CR20200326A (es) Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer.
IL309208A (en) Neuroactive steroid for the treatment of alzheimer's disease
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
BR112020022088A8 (pt) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina
AR067560A1 (es) Bencenosulfonil-cromano, tiocromano, tetrahidronaftaleno como inhibidores de la gamma secretasa, composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades neurodegenerativas.
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
MX2019007104A (es) Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
BR112022021743A2 (pt) Compostos e métodos direcionando a interleucina-34
CL2019003562A1 (es) Derivados esteroideos con actividad terapéutica.
CO6270365A2 (es) Derivado heterociclico con una sal farmaceuticamente aceptable o solvato del mismo y composicion que lo comprende
MX388366B (es) Composiciones para tratar enfermedades neurodegenerativas.
EA202191521A1 (ru) 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний
BRPI0817433A2 (pt) Moduladores de gama-secretase piperidinila e piperazinila
GT200700097A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
UY28825A1 (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos